Breaking News
March 20, 2019 - Biohaven’s Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy
March 20, 2019 - Smoking may limit body’s ability to fight dangerous form of skin cancer
March 20, 2019 - Researchers receive $9.7-million grant to develop new hearing-loss treatments for deaf
March 20, 2019 - TGen and ABL sign agreement to distribute new TB test technology
March 20, 2019 - UCD researchers lead development of new urine test to detect prostate cancer
March 20, 2019 - Miniature brains that can move muscles, grown in the lab
March 20, 2019 - Servier and Oncodesign announce research and drug development partnership
March 20, 2019 - FDA warns marketer of unapproved products claiming to treat addiction, chronic pain
March 20, 2019 - TB Medicine Pretomanid Enters Regulatory Review Process in the United States
March 20, 2019 - Breastfeeding can erase effects of prenatal violence for newborns
March 20, 2019 - Tens of Thousands of Heart Patients May Not Need Open-Heart Surgery
March 20, 2019 - Space worries – shingles affecting astronauts says NASA
March 20, 2019 - Study shows how AI can improve physicians’ diagnostic accuracy
March 20, 2019 - Dolomite Bio launches new scRNA-Seq Reagent Kit at AGBT 2019
March 20, 2019 - World’s oldest semen viable for artificial insemination
March 20, 2019 - FDA Approves Zulresso (brexanolone) for the Treatment of Post-Partum Depression
March 19, 2019 - How it manipulates us to tribalism
March 19, 2019 - How can doctors encourage patients to adopt healthier behaviors?
March 19, 2019 - Meet Hal: He's One Sick Robot
March 19, 2019 - Blood test and mathematical model can estimate preterm birth rate in low-resource countries
March 19, 2019 - TAVR procedure safe in patients with unusual valve anatomy
March 19, 2019 - Proteins in the eye may be potential source for cost-effective test to predict Alzheimer’s disease
March 19, 2019 - Opioid Prescriptions Dropped for New Users From 2012 to 2017
March 19, 2019 - New method may better predict the best treatment for burn wounds
March 19, 2019 - “Asian” isn’t specific enough for health data, research suggests
March 19, 2019 - ColumbiaDoctors Presents Honors for Outstanding Commitment to Patient Safety
March 19, 2019 - Innovative model identifies primate species with potential to transmit Zika in the Americas
March 19, 2019 - One-off surgery could offer hope to patients with high blood pressure
March 19, 2019 - Many pet owners interested in feeding their pets with plant-based diet
March 19, 2019 - How to Protect Your Kids From Drowning
March 19, 2019 - CEA Test: MedlinePlus Lab Test Information
March 19, 2019 - Two years after face transplant, Andy Sandness’ smile shows his progress
March 19, 2019 - Registration now open for Stanford’s Big Data in Precision Health conference
March 19, 2019 - Gene Keeps Fear at Bay, But Only in Females
March 19, 2019 - Cholesterol lowering drug can also help treat cancer-associated cachexia
March 19, 2019 - GARDP and Evotec partner to tackle growing threat of antimicrobial resistance
March 19, 2019 - Ultrasound offers precise, minimally invasive way to measure cardiac output in children
March 19, 2019 - Study suggests potential new approach to treat atopic dermatitis
March 19, 2019 - Sense of control over life makes older adults feel younger
March 19, 2019 - Study shows how probiotics influence gut microbiota
March 19, 2019 - Study offers new evidence that narcolepsy is an autoimmune condition
March 19, 2019 - Breastfeeding may offer long-term heart health benefits for women
March 19, 2019 - Study of young athletes suggests snoring and sleep apnea are linked to sudden cardiac death
March 19, 2019 - Did Your Doctor ‘Ghost’ You? An Employment Contract May Be To Blame
March 19, 2019 - Food pantry clients more likely to make healthy choices when meal kits and recipe tastings are available
March 19, 2019 - Mental health problems among children increasing
March 19, 2019 - New ISO standard helps evaluate and manage impact of environmental damage
March 19, 2019 - CardioMEMS heart failure sensor reliably safe, effectively reduces hospitalizations
March 19, 2019 - Researchers report promising results of potential reversal agent
March 19, 2019 - Scientists identify brain circuit responsible for cocaine-seeking behavior during relapse
March 19, 2019 - First African-American Neuroscience Research Initiative launched to close the gap in health disparities
March 19, 2019 - Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study
March 19, 2019 - Attitudes about health affect how older adults engage with negative health news
March 19, 2019 - Huron Digital Pathology to unveil new ‘Scan Index Search’ platform at USCAP 2019
March 19, 2019 - Frequent intake of sugary drinks tied to greater risk of premature death
March 19, 2019 - Bruker showcases new analytical systems and applied market solutions at Pittcon 2019
March 19, 2019 - Framingham cardiovascular risk prediction model from the 1990s still gives the best results
March 19, 2019 - New article focuses on integrative health, value-based medicine, and whole systems research
March 19, 2019 - Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne
March 19, 2019 - National survey of emergency dept management of self-harm highlights successes, room for improvement
March 19, 2019 - Scientists reverse alcohol-seeking behavior in rats with flip of a switch
March 19, 2019 - Researchers hope blood test that accurately diagnoses fibromyalgia could be available within five years
March 19, 2019 - New Planmeca ProScanner 2.0 offers fast and dependable intraoral imaging
March 19, 2019 - A new option for reducing LDL cholesterol in patients at high risk for heart attack, stroke
March 19, 2019 - Common medications to treat heartburn linked to increased risks for kidney failure
March 19, 2019 - Current HBV genome sequences help deduce ancient human population movements into Australia
March 19, 2019 - Pure omega-3 prescription drug significantly reduces the occurrence of ischemic events
March 19, 2019 - Researchers use big data to gain better understanding of hepatitis E virus
March 19, 2019 - Use of synthetic psychedelic linked to improvements in depression and anxiety
March 19, 2019 - GARP protein can be a potential target for immunotherapy against colorectal cancer
March 19, 2019 - Knee Pain Not Tied to Activity Levels in Knee Osteoarthritis
March 19, 2019 - Study shows benefits of delayed cord clamping in healthy babies
March 19, 2019 - Pharmacists can undertake overall clinical responsibility for patients, shows study
March 19, 2019 - A cell’s “self-destruct” function could yield new therapies
March 19, 2019 - Latest advances and perspectives of all AI types used in pharmaceutical R&D
March 19, 2019 - Prophylactic cranial irradiation used as standard approach for patients with NSCLC
March 19, 2019 - Sugar-sweetened beverages may be linked with increased risk of cardiovascular mortality
March 19, 2019 - AHA News: Black Woman in Their 50s Face Especially High Stroke Risk
March 19, 2019 - Secrets of early life revealed from less than half a teaspoon of blood
March 19, 2019 - Immune cells engineered to tattle on suspicious cells in the body
New gene therapy treatment for Sickle Cell Anemia reverses symptoms in adults

New gene therapy treatment for Sickle Cell Anemia reverses symptoms in adults

image_pdfDownload PDFimage_print

After over a decade of preclinical research and development, a new gene therapy treatment for Sickle Cell Anemia (SCA) is reversing disease symptoms in two adults and showing early potential for transportability to resource-challenged parts of the world where SCA is most common.

Preliminary data from a pilot Phase 1-2 clinical trial testing the gene-addition therapy were presented Dec. 3 at the American Society of Hematology’s (ASH) annual meeting in San Diego by principal investigator Punam Malik, MD. She is a physician-scientist at the Cincinnati Children’s Cancer and Blood Diseases Institute and director of its Comprehensive Sickle Cell Center. Malik called the data promising.

“One year after treatment of our first patient, and six months after treatment of our second patient, both have seen a remarkable improvement in the quality of life due to remarkable reduction in disease symptoms. This includes near elimination of chronic pain and sickling events and improved anemia,” Malik said. “Although it’s still early post-treatment, these preliminary results are quite promising. If sustained this therapy will provide a transportable, safe and feasible gene therapy for all SCA patients.”

SCA is a painful, inherited disease where blood cells become sickle-shaped and stuck in the vascular system. It can damage vital organs and cause death.

How the Therapy Works

The gene therapy developed by Cincinnati Children’s uses a modified gamma globin lentivirus vector to transfer a healthy fetal hemoglobin gene into a patient’s blood stem cells (hematopoietic stem cells, HSC). The lentivirus is modified so it does not cause illness.

The therapy comes from the observation that some adults never stop producing fetal hemoglobin (HbF). This prevents red blood cell sickling when sufficient quantities of HbF are present in the body.

Normally, the fetal hemoglobin gene switches off shortly after birth. The new gene therapy approach designed by Malik and team places a fetal hemoglobin gene in the bone marrow cells that cannot switch off.

Cells are collected earlier from the SCA patient and genetically reprogrammed in a clean lab facility with the modified lentivirus vector. Then the patient’s bone marrow is preconditioned with one low-dose of chemotherapy, after which the gene-corrected cells are infused back into the patient. Patients recover their blood counts within a week to 10 days and recover from the chemotherapy effects by two weeks, Malik said.

A key feature of the treatment regimen is the reduced-intensity preconditioning for patients receiving the therapy for SCA. The method is less toxic and expensive than myeloablative preconditioning normally used in bone marrow transplants, according to the researchers.

Myeloablative conditioning uses high-intensity chemotherapy to prepare a transplant patient’s bone marrow for healthy gene-corrected blood stem cells (HSCs). This typically results in low blood counts and other side effects. These can include severe infections and long stays in transplant units for one or two months.

This means transplants using myeloablative conditioning have to be performed at large and sophisticated medical centers in developed parts of the world. Malik said this limits access to people in underdeveloped regions where SCA is more common, like Africa, India, the Caribbean and South America.

Reaching High-Need Regions

One goal for Malik and her colleagues is that their therapy’s reduced intensity conditioning will allow it to be offered at hospitals in places like Central Africa and other underdeveloped regions of the world.

SCA affects more than 90,000 people in the United States, and millions of people worldwide have the disease, according to the researchers.

Malik said additional data from the study will tell investigators of the consistent and long-term clinical benefit of this therapy to patients with severe SCA. The trial is scheduled to treat up to 10 patients with SCA. Preclinical studies by the research team suggested the treatment allows the body to produce normal red blood cells instead of the sickle-shaped cells that define the inherited disorder.

Improved Quality of Life

Both adult patients included in the ASH presentation are 35 and 25 years old who, respectively, had gene transfer therapy 15 and 12 months ago. In the year and a half prior to receiving gene-correction therapy, both patients had more than a dozen acute sickle events per year, according to Malik. These included acute chest and pain crises, chronic pain, and required the ongoing use of oral or injectable opioids on a regular basis.

Investigators report that one year following therapy, the first patient no longer requires daily oral opioids for chronic pain and has had one acute sickle cell event. The second patient no longer uses oral opioids and has no vaso-occlusive events, where blood cells become stuck in the vascular system.

Launch of Aruvant Sciences

In an effort to accelerate the development of the therapy, Cincinnati Children’s has partnered with Roivant Sciences to create Aruvant Sciences. The joint venture is focused on developing and commercializing innovative therapies for hematological conditions. Aruvant’s lead candidate is RVT-1801, the gene therapy used to treat both patients in Malik’s ASH presentation of early clinical trial data. Aruvant Sciences will be based in Cincinnati.

Source:

https://www.cincinnatichildrens.org/

Tagged with:

About author

Related Articles